NCT00119639View on ClinicalTrials.gov

Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2005

Study Completion Date

December 31, 2005

Conditions
Kidney Diseases
Interventions
DRUG

Sorafenib (BAY43-9006, Nexavar)

All subjects were given a open-label, single dose of 400mg sorafenib

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY